A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
Authors:
- the Polish Hereditary Prostate Cancer ConsortiumTCthe Polish Hereditary Prostate Cancer Consortium
- C CybulskiCCC Cybulski
- D WokołorczykDWD Wokołorczyk
- W KluźniakWKW Kluźniak
- A KashyapAKA Kashyap
- M SłojewskiM Słojewski
- A SikorskiASA Sikorski
- T BorkowskiTBT Borkowski
- A BorkowskiABA Borkowski
Open Access
- 30 May 2013
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (12) , 2601-2609
Abstract
To evaluate whether genotyping for 18 prostate cancer founder variants is helpful in identifying high-risk individuals and for determining optimal screening regimens. A serum PSA level was measured and a digital rectal examination (DRE) was performed on 2907 unaffected men aged 40-90. Three hundred and twenty-three men with an elevated PSA (≥4 ng ml⁻¹) or an abnormal DRE underwent a prostate biopsy. All men were genotyped for three founder alleles in BRCA1 (5382insC, 4153delA and C61G), for four alleles in CHEK2 (1100delC, IVS2+1G>A, del5395 and I157T), for one allele in NBS1 (657del5), for one allele in HOXB13 (G84E), and for nine low-risk single-nucleotide polymorphisms (SNPs). On the basis of an elevated PSA or an abnormal DRE, prostate cancer was diagnosed in 135 of 2907 men (4.6%). In men with a CHEK2 missense mutation I157T, the cancer detection rate among men with an elevated PSA or an abnormal DRE was much higher (10.2%, P=0.0008). The cancer detection rate rose with the number of SNP risk genotypes observed from 1.2% for men with no variant to 8.6% for men who carried six or more variants (P=0.04). No single variant was helpful on its own in predicting the presence of prostate cancer, however, the combination of all rare mutations and SNPs improved predictive power (area under the curve=0.59; P=0.03). These results suggest that testing for germline CHEK2 mutations improves the ability to predict the presence of prostate cancer in screened men, however, the clinical utility of incorporating DNA variants in the screening process is marginal.Keywords
This publication has 52 references indexed in Scilit:
- Screening for prostate cancerCochrane Database of Systematic Reviews, 2013
- Germline BRCA1 mutations increase prostate cancer riskBritish Journal of Cancer, 2012
- Evaluation of Multiple Risk–Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened MenEuropean Urology, 2011
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBritish Journal of Cancer, 2011
- Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyNature Genetics, 2011
- Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21Nature Genetics, 2011
- Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosisBritish Journal of Cancer, 2010
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyNature Genetics, 2009
- Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibilityNature Genetics, 2009
- Rapid progression of prostate cancer in men with a BRCA2 mutationBritish Journal of Cancer, 2008